Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of BI 473494 in Healthy Males
NCT03195088Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 473494 in obesity (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of Participants With Drug-related Adverse Events up to 40 days. Started Jul 2017; status: terminated.
02
Drugs
BI 473494
03
Conditions
obesity
Beyond the preview
Go deeper on NCT03195088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03195088.